LIFE-CHANGING TECH DELIVERS EXCEPTIONAL GROWTH

**SALES WORLDWIDE**

$8.1 billion

+7.6% on organic basis

**STRONG PERFORMANCE ACROSS ABBOTT**

SALES ON ORGANIC BASIS

+10.6% MEDICAL DEVICES

+6.6% DIAGNOSTICS

+3.8% NUTRITION

+7.9% DISTRIBUTED BUSINESSES

**NARROWED FULL-YEAR 2019 EPS GUIDANCE**

$3.23 to $3.25

Adjusted diluted EPS midpoint reflects double-digit growth

**KEY PRODUCTS DRIVE EXCEPTIONAL PERFORMANCE**

**FREESTYLE LIBRE**

SALES UP 68% ON ORGANIC BASIS

**MitraClip**

SALES UP 32% ON ORGANIC BASIS

**CORE LABORATORY DIAGNOSTICS**

SALES UP 11% ON ORGANIC BASIS

**FORWARD-LOOKING STATEMENTS**

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

**NARRATIVE**

**LIFE-CHANGING TECH DELIVERS EXCEPTIONAL GROWTH**

**FREESTYLE LIBRE**

The FreeStyle Libre, the first sensor-based glucose monitoring system listed in any Canadian provincial health plan, gained public reimbursement in Ontario and Quebec.

**ABBOTT ENTERS NEW COLLABORATIONS**

Abbott enters new collaborations with Sanofi, Omada Health and Tandem Diabetes Care to provide people with diabetes a connected device experience.

**MITRALCLIP SALES UP ON ORGANIC BASIS**

32% on organic basis

**STRONG PERFORMANCE ACROSS ABBOTT**

SALES ON ORGANIC BASIS

+10.6% MEDICAL DEVICES

+6.6% DIAGNOSTICS

+3.8% NUTRITION

+7.9% DISTRIBUTED BUSINESSES

**NARROWED FULL-YEAR 2019 EPS GUIDANCE**

$3.23 to $3.25

Adjusted diluted EPS midpoint reflects double-digit growth

**KEY PRODUCTS DRIVE EXCEPTIONAL PERFORMANCE**

**FREESTYLE LIBRE**

SALES UP 68% ON ORGANIC BASIS

**MITRALCLIP**

SALES UP 32% ON ORGANIC BASIS

**CORE LABORATORY DIAGNOSTICS**

SALES UP 11% ON ORGANIC BASIS

**FORWARD-LOOKING STATEMENTS**

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

**NARRATIVE**

**LIFE-CHANGING TECH DELIVERS EXCEPTIONAL GROWTH**

**FREESTYLE LIBRE**

The FreeStyle Libre, the first sensor-based glucose monitoring system listed in any Canadian provincial health plan, gained public reimbursement in Ontario and Quebec.

**ABBOTT ENTERS NEW COLLABORATIONS**

Abbott enters new collaborations with Sanofi, Omada Health and Tandem Diabetes Care to provide people with diabetes a connected device experience.

**MITRALCLIP SALES UP ON ORGANIC BASIS**

32% on organic basis

**STRONG PERFORMANCE ACROSS ABBOTT**

SALES ON ORGANIC BASIS

+10.6% MEDICAL DEVICES

+6.6% DIAGNOSTICS

+3.8% NUTRITION

+7.9% DISTRIBUTED BUSINESSES

**NARROWED FULL-YEAR 2019 EPS GUIDANCE**

$3.23 to $3.25

Adjusted diluted EPS midpoint reflects double-digit growth

**KEY PRODUCTS DRIVE EXCEPTIONAL PERFORMANCE**

**FREESTYLE LIBRE**

SALES UP 68% ON ORGANIC BASIS

**MITRALCLIP**

SALES UP 32% ON ORGANIC BASIS

**CORE LABORATORY DIAGNOSTICS**

SALES UP 11% ON ORGANIC BASIS

**FORWARD-LOOKING STATEMENTS**

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

**NARRATIVE**

**LIFE-CHANGING TECH DELIVERS EXCEPTIONAL GROWTH**

**FREESTYLE LIBRE**

The FreeStyle Libre, the first sensor-based glucose monitoring system listed in any Canadian provincial health plan, gained public reimbursement in Ontario and Quebec.

**ABBOTT ENTERS NEW COLLABORATIONS**

Abbott enters new collaborations with Sanofi, Omada Health and Tandem Diabetes Care to provide people with diabetes a connected device experience.

**MITRALCLIP SALES UP ON ORGANIC BASIS**

32% on organic basis

**STRONG PERFORMANCE ACROSS ABBOTT**

SALES ON ORGANIC BASIS

+10.6% MEDICAL DEVICES

+6.6% DIAGNOSTICS

+3.8% NUTRITION

+7.9% DISTRIBUTED BUSINESSES

**NARROWED FULL-YEAR 2019 EPS GUIDANCE**

$3.23 to $3.25

Adjusted diluted EPS midpoint reflects double-digit growth

**KEY PRODUCTS DRIVE EXCEPTIONAL PERFORMANCE**

**FREESTYLE LIBRE**

SALES UP 68% ON ORGANIC BASIS

**MITRALCLIP**

SALES UP 32% ON ORGANIC BASIS

**CORE LABORATORY DIAGNOSTICS**

SALES UP 11% ON ORGANIC BASIS

**FORWARD-LOOKING STATEMENTS**

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

**NARRATIVE**

**LIFE-CHANGING TECH DELIVERS EXCEPTIONAL GROWTH**

**FREESTYLE LIBRE**

The FreeStyle Libre, the first sensor-based glucose monitoring system listed in any Canadian provincial health plan, gained public reimbursement in Ontario and Quebec.

**ABBOTT ENTERS NEW COLLABORATIONS**

Abbott enters new collaborations with Sanofi, Omada Health and Tandem Diabetes Care to provide people with diabetes a connected device experience.

**MITRALCLIP SALES UP ON ORGANIC BASIS**

32% on organic basis

**STRONG PERFORMANCE ACROSS ABBOTT**

SALES ON ORGANIC BASIS

+10.6% MEDICAL DEVICES

+6.6% DIAGNOSTICS

+3.8% NUTRITION

+7.9% DISTRIBUTED BUSINESSES

**NARROWED FULL-YEAR 2019 EPS GUIDANCE**

$3.23 to $3.25

Adjusted diluted EPS midpoint reflects double-digit growth

**KEY PRODUCTS DRIVE EXCEPTIONAL PERFORMANCE**

**FREESTYLE LIBRE**

SALES UP 68% ON ORGANIC BASIS

**MITRALCLIP**

SALES UP 32% ON ORGANIC BASIS

**CORE LABORATORY DIAGNOSTICS**

SALES UP 11% ON ORGANIC BASIS

**FORWARD-LOOKING STATEMENTS**

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.